

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the prospectus dated Wednesday, November 20, 2024 (the “**Prospectus**”) issued by Hangzhou Jiuyuan Gene Engineering Co., Ltd. (杭州九源基因工程股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, Huatai Financial Holdings (Hong Kong) Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period on and after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Wednesday, December 25, 2024, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the H Shares could fall.

Potential investors of the Offer Shares should note that the Sole Sponsor and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.



Hangzhou Jiuyuan Gene Engineering Co., Ltd.

杭州九源基因工程股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

- Number of Offer Shares under the Global Offering** : 45,398,800 H Shares (subject to the Over-allotment Option)
- Number of Hong Kong Offer Shares** : 4,540,000 H Shares (subject to reallocation)
- Number of International Offer Shares** : 40,858,800 H Shares (subject to reallocation and the Over-allotment Option)
- Maximum Offer Price** : HK\$12.56 per H Share (plus brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565%, payable in full in Hong Kong dollars on application and subject to refund)
- Nominal value** : RMB1.00 per H Share
- Stock code** : 2566

*Sole Sponsor, Overall Coordinator, Joint Global Coordinator,
Joint Bookrunner and Joint Lead Manager*

华泰国际

**IMPORTANT NOTICE TO INVESTORS
OF HONG KONG OFFER SHARES**

FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering.

The Prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “HKEXnews > New Listings > New Listing Information” section, and the website of the Company at www.china-gene.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

342

(1) **White Form eIPO** www.eipo.com.hk;

(2) **HKSCC EIPO** www.hkscceipo.com **broker** **custodian**
electronic application instructions

intermediary, broker agent,

A

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (Stock Code: 2566)
(HK\$12.56 per Hong Kong Offer Share)


**NUMBER OF HONG KONG OFFER SHARES
 THAT MAY BE APPLIED FOR AND PAYMENTS**

No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application HK\$	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application HK\$	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application HK\$	No. of Hong Kong Offer Shares applied for	Amount payable ⁽²⁾ on application HK\$
200	2,537.33	4,000	50,746.68	60,000	761,200.06	450,000	5,709,000.42
400	5,074.67	5,000	63,433.34	70,000	888,066.73	500,000	6,343,333.80
600	7,612.00	6,000	76,120.00	80,000	1,014,933.41	600,000	7,612,000.55
800	10,149.34	7,000	88,806.67	90,000	1,141,800.09	700,000	8,880,667.32
1,000	12,686.67	8,000	101,493.34	100,000	1,268,666.75	800,000	10,149,334.08
1,200	15,224.00	9,000	114,180.01	150,000	1,903,000.15	900,000	11,418,000.85
1,400	17,761.33	10,000	126,866.68	200,000	2,537,333.52	1,000,000	12,686,667.60
1,600	20,298.67	20,000	253,733.35	250,000	3,171,666.90	1,500,000	19,030,001.40
1,800	22,836.00	30,000	380,600.03	300,000	3,806,000.28	2,000,000	25,373,335.20
2,000	25,373.34	40,000	507,466.70	350,000	4,440,333.65	2,270,000 ⁽¹⁾	28,798,735.45
3,000	38,060.01	50,000	634,333.38	400,000	5,074,667.05		


(1) The number of Hong Kong Offer Shares applied for is subject to the availability of the Hong Kong Offer Shares.

(2) The amount payable on application is calculated based on the application fee of HK\$12.56 per Hong Kong Offer Share applied for. The amount payable on application is subject to the availability of the Hong Kong Offer Shares.


THE LISTING APPLICATION



STRUCTURE OF THE GLOBAL OFFERING



PRICING



EXPECTED TIMETABLE⁽¹⁾

H		9:00	20, 2024
▲	White Form eIPO www.eipo.com.hk	11:30	25, 2024
A		11:45	25, 2024
▲	() White Form eIPO () () () electronic application instructions	12:00	25, 2024
	broker custodian electronic application instructions		
	broker custodian.		
A		12:00	25, 2024
			26, 2024

A

www.hkexnews.hk

www.china-gene.com

11:00

27, 2024

A

www.hkexnews.hk

www.china-gene.com

11:00

27, 2024

www.iporeresults.com.hk (

www.eipo.com.hk/eIPOAllotment)

24-

11:00

27, 2024

12:00

3, 2024

A

+852 2862 8555

9:00

6:00

28, 2024

3, 2024

A
27, 2024

27, 2024

White Form
()
()
28, 2024

9:00
28, 2024

Note:

(1) A

SETTLEMENT

A

ELECTRONIC APPLICATION CHANNELS

2024 12:00 9:00 25, 2024 (H) 20,

H

Application Channel Platform Target Investors Application Time

White Form eIPO Service www.eipo.com.hk

9:00
20, 2024 11:30
25,
2024, H
12:00
25, 2024, H

HKSCC EIPO channel

broker custodian

broker
custodian
broker
custodian.

White Form eIPO

HKSCC EIPO

White Form eIPO

28, 2024.

HKSCC EIPO

H A

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, and on the designated website at www.eipo.com.hk for the White Form eIPO service.

PUBLICATION OF RESULTS

www.hkexnews.hk www.china-gene.com 11:00
27, 2024 (H)
A 12.5()5()12 .12.5(,5() (A 2.5()12 .)12.6())18

2566. 28, 2024, 9:00 200 8:00 28, 2024.
www.hkexnews.hk www.china-gene.com

Hangzhou Jiuyuan Gene Engineering Co., Ltd.

杭州九源基因工程股份有限公司

FU Hang

Executive Director, Chairman of the Board and General Manager

20, 2024

As at the date of this announcement, the Board comprises Mr. FU Hang (傅航) and Mr. ZHOU Wei (周偉) as executive Directors; Ms. MA Honglan (馬紅蘭), Mr. WU Shihang (吳詩航), Mr. Albert ESTEVE Cruella and Mr. FEI Junjie (費俊傑) as non-executive Directors; and Dr. ZHOU Zhihui (周智慧), Dr. ZHOU Demin (周德敏) 錨瘁 . 穫衣 蝦悞腰融正揷辟灼青滯